Canada· CA-DIN-02464616

FIBRYGA

A fibrinogen, human product containing fibrinogen (human), registered in Canada by OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H. The same ATC class is registered in 11 of our 19 countries.

ATC B02BB01

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedFIBRYGAATCB02BB01REGISTER NO.CA-DIN-02464616PACKS LISTED0CHECKEDOctober 1, 2026

Where it is registered

Fibrinogen, human is registered in 11 of 19 countries.

Countries holding a registration under ATC B02BB01 (fibrinogen, human), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 7 of them publish a price we can compare per daily dose

Fibrinogen, human · ATC B02BB01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of fibrinogen, human costs, country by country.

Normalised to the WHO defined daily dose (5 g), the median price runs from $2.30 in Czechia to $2694.05 in Switzerland — a ×1171 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Fibrinogen, human · price per daily dose (5 g)

USD · FX 28 Sept 2026

  • CH Switzerland$2694.05
  • CZ Czechia$2.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
FIBRINOGEN (HUMAN)
Manufacturer
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
Country
Canada (CA)
ATC code
B02BB01
ATC class
Fibrinogen, human
Defined daily dose
5 g, P
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for fibrinogen, human.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fibrinogen, human · interactions on record

2 records

  • 2 severe

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fibrinogen, human in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fibrinogen, human products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Fibclot, Fibryga
  • Belgium · Fibclot, Fibryga
  • Bulgaria · Fibryga, Хемокомплетан P
  • Cyprus · Fibryga, Riastap
  • Czechia · Fibryga, Haemocomplettan P
  • Germany · Fibclot, Fibryga
  • Denmark · Fibclot, Fibryga
  • Estonia · Fibryga
  • Spain · Fibclot, Fibryga
  • Finland · Fibclot, Fibryga
  • France · Clottafact, Fibryga
  • United Kingdom (Northern Ireland) · Fibclot, Fibryga
  • Greece · Fibclot, Riastap
  • Croatia · Fibryga
  • Hungary · Fibclot, Fibryga
  • Ireland · Fibryga, Riastap
  • Iceland · Fibryga, Riastap
  • Italy · Fibriclotte, Fibryga
  • Lithuania · Fibryga
  • Luxembourg · Fibclot, Fibryga
  • Latvia · Fibryga
  • Malta · Fibryga, Riastap
  • Netherlands · Fibclot, Fibryga
  • Norway · Fibclot, Fibryga
  • Poland · Fibryga, Riastap
  • Portugal · Fibryga, Haemocomplettan
  • Romania · Fibryga, Haemocomplettan P
  • Sweden · Fibclot, Fibryga
  • Slovenia · Fibrema, Prufibry
  • Slovakia · Fibryga, Riastap

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0878b3bc-3ccc-4283-b245-f55bf2934f1d
GET /v1/drugs/0878b3bc-3ccc-4283-b245-f55bf2934f1d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02464616",
  "form": "POWDER FOR SOLUTION",
  "class": "Human",
  "routes": [
    "INTRAVENOUS"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "B02BB01",
  "schedule": [
    "Schedule D"
  ],
  "drug_code": "95274",
  "strengths": [
    "1 G"
  ],
  "ahfs_class": null,
  "substances": [
    "FIBRINOGEN (HUMAN)"
  ],
  "product_categorization": null
}

See everything about fibrinogen, human.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.